Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
24-Oct-2007
According to the company, with its acquisition of Bioenvision, Genzyme takes a significant step in enhancing its existing oncology business by gaining the exclusive, worldwide rights to clofarabine.
Genzyme acquires Bioenvision in an all cash transaction valued at $5.60 per share, or approximately $345 million.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.